Literature DB >> 34041698

Middle Ear "Adenoma": a Neuroendocrine Tumor with Predominant L Cell Differentiation.

Sylvia L Asa1, Knarik Arkun2, Arthur S Tischler2, Adnan Qamar2, Fang-Ming Deng3, Bayardo Perez-Ordonez4, Ilan Weinreb4, Justin A Bishop5, Bruce M Wenig6, Ozgur Mete4.   

Abstract

This morphological and immunohistochemical study demonstrates that tumors currently known as "middle ear adenomas" are truly well-differentiated epithelial neuroendocrine tumors (NETs) composed of cells comparable to normal intestinal L cells, and therefore, these tumors resemble hindgut NETs. These tumors show consistent expression of glucagon, pancreatic polypeptide, PYY, and the transcription factor SATB2, as well as generic neuroendocrine markers and keratins. The same L cell markers are expressed by cells within the normal middle ear epithelium. These markers define a valuable immunohistochemical profile that can be used for differential diagnosis of middle ear neoplasms, particularly in distinguishing epithelial NETs from paragangliomas. The discovery of neuroendocrine cells expressing the same markers in non-neoplastic middle ear mucosa opens new areas of investigation into the physiology of the normal middle ear and the pathophysiology of middle ear disorders.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  L cell; Middle ear adenoma; Neuroendocrine tumor

Mesh:

Year:  2021        PMID: 34041698     DOI: 10.1007/s12022-021-09684-z

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  2 in total

1.  SATB2 is a sensitive marker for lower gastrointestinal well-differentiated neuroendocrine tumors.

Authors:  Zhongwu Li; Jing Yuan; Lixin Wei; Lixin Zhou; Kaiyong Mei; Junqiu Yue; Hongwen Gao; Miao Zhang; Ling Jia; Qiang Kang; Xiaozheng Huang; Dengfeng Cao
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

2.  Light and electron microscopic studies of a case of middle ear adenoma.

Authors:  X Kochilas; J P Birchall; P Sloan
Journal:  Laryngoscope       Date:  1984-11       Impact factor: 3.325

  2 in total
  5 in total

Review 1.  Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.

Authors:  Ozgur Mete; Sylvia L Asa; Anthony J Gill; Noriko Kimura; Ronald R de Krijger; Arthur Tischler
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

2.  Clinical and histopathological principles for the diagnosis of a recurrent paraganglioma of the jugular foramen initially diagnosed as a middle ear adenoma: illustrative case.

Authors:  Jeffrey M Breton; Knarik Arkun; Arthur S Tischler; Adnan S Qamar; Jonathan S Sillman; Carl B Heilman
Journal:  J Neurosurg Case Lessons       Date:  2021-08-02

Review 3.  Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms.

Authors:  Ozgur Mete; Bruce M Wenig
Journal:  Head Neck Pathol       Date:  2022-03-21

4.  Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumours: Tumours of the Ear.

Authors:  Ann Sandison
Journal:  Head Neck Pathol       Date:  2022-04-09

5.  Middle ear neuroendocrine tumor: a case report.

Authors:  Azeddine Lachkar; Drissia Benfadil; Fahd Elayoubi
Journal:  J Surg Case Rep       Date:  2022-06-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.